Signifor FDA Approval History
FDA Approved: Yes (First approved December 14, 2012)
Brand name: Signifor
Generic name: pasireotide
Dosage form: Injection
Company: Novartis Pharmaceuticals Corporation
Treatment for: Cushing's Syndrome
Signifor (pasireotide) is a multireceptor targeting somatostatin analog for the treatment of patients with Cushing's disease.
Development timeline for Signifor
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
